CN117279922B - Tyk2抑制剂及其用途 - Google Patents

Tyk2抑制剂及其用途

Info

Publication number
CN117279922B
CN117279922B CN202180076687.5A CN202180076687A CN117279922B CN 117279922 B CN117279922 B CN 117279922B CN 202180076687 A CN202180076687 A CN 202180076687A CN 117279922 B CN117279922 B CN 117279922B
Authority
CN
China
Prior art keywords
alkyl
pharmaceutically acceptable
compounds
disease
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180076687.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN117279922A (zh
Inventor
B·靳
Q·董
G·洪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arumis Inc
Original Assignee
Arumis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arumis Inc filed Critical Arumis Inc
Publication of CN117279922A publication Critical patent/CN117279922A/zh
Application granted granted Critical
Publication of CN117279922B publication Critical patent/CN117279922B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180076687.5A 2020-09-16 2021-09-16 Tyk2抑制剂及其用途 Active CN117279922B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063079217P 2020-09-16 2020-09-16
US63/079,217 2020-09-16
PCT/US2021/050649 WO2022060973A1 (en) 2020-09-16 2021-09-16 Tyk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
CN117279922A CN117279922A (zh) 2023-12-22
CN117279922B true CN117279922B (zh) 2025-12-19

Family

ID=78086111

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180076687.5A Active CN117279922B (zh) 2020-09-16 2021-09-16 Tyk2抑制剂及其用途

Country Status (9)

Country Link
US (1) US20230357273A1 (https=)
EP (1) EP4214215A1 (https=)
JP (1) JP7824938B2 (https=)
KR (1) KR20230069984A (https=)
CN (1) CN117279922B (https=)
AU (1) AU2021345181A1 (https=)
CA (1) CA3192621A1 (https=)
IL (1) IL301385A (https=)
WO (1) WO2022060973A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス， インコーポレイテッド Ｔｙｋ２分解剤およびそれらの使用
JP2025509596A (ja) * 2022-03-16 2025-04-11 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
WO2023178235A1 (en) * 2022-03-16 2023-09-21 Alumis Inc. Tyk2 inhibitors and uses thereof
WO2023208244A1 (zh) * 2022-04-29 2023-11-02 南京明德新药研发有限公司 大环类化合物及其应用
WO2024199479A1 (zh) 2023-03-31 2024-10-03 北京普祺医药科技股份有限公司 一种大环化合物、药物组合物及其用途
WO2024222807A1 (en) * 2023-04-27 2024-10-31 Hangzhou Highlightll Pharmaceutical Co., Ltd Novel macrocyclic heteroaryl derivatives as kinase inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020185755A1 (en) * 2019-03-11 2020-09-17 Fronthera U.S. Pharmaceuticals Llc Tyk2 inhibitors and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2864839T3 (es) * 2015-07-02 2021-10-14 Turning Point Therapeutics Inc Macrociclos de diarilo quirales como moduladores de proteína quinasas
US10479793B2 (en) * 2015-11-18 2019-11-19 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
ES2902995T3 (es) * 2016-10-07 2022-03-30 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN120865208A (zh) * 2019-01-23 2025-10-31 武田药品工业株式会社 Tyk2抑制剂和其用途
US20220135567A1 (en) * 2019-02-07 2022-05-05 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands
AU2020247990A1 (en) * 2019-03-26 2021-11-11 Ventyx Biosciences, Inc. TYK2 pseudokinase ligands

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020185755A1 (en) * 2019-03-11 2020-09-17 Fronthera U.S. Pharmaceuticals Llc Tyk2 inhibitors and uses thereof

Also Published As

Publication number Publication date
AU2021345181A9 (en) 2024-06-20
WO2022060973A1 (en) 2022-03-24
CA3192621A1 (en) 2022-03-24
AU2021345181A1 (en) 2023-05-04
IL301385A (en) 2023-05-01
JP2023541203A (ja) 2023-09-28
CN117279922A (zh) 2023-12-22
US20230357273A1 (en) 2023-11-09
KR20230069984A (ko) 2023-05-19
EP4214215A1 (en) 2023-07-26
JP7824938B2 (ja) 2026-03-05

Similar Documents

Publication Publication Date Title
CN117279922B (zh) Tyk2抑制剂及其用途
EP3870579B1 (en) Tyk2 inhibitors and uses thereof
AU2017345736B2 (en) TYK2 inhibitors and uses thereof
CA2933480C (en) Inhibitors of lysine specific demethylase-1
CN113811534B (zh) Tyk2抑制剂和其用途
CN106660987B (zh) 赖氨酸特异性脱甲基酶-1的抑制剂
EP4493281A1 (en) Tyk2 inhibitors and uses thereof
JP2025509594A (ja) Ｔｙｋ２阻害剤およびその使用
HK40105557B (zh) Tyk2抑制剂及其用途
HK40105557A (zh) Tyk2抑制剂及其用途
HK40120037A (en) Tyk2 inhibitors and uses thereof
HK40119624A (en) Tyk2 inhibitors and uses thereof
HK40063819A (en) Tyk2 inhibitors and uses thereof
HK40120037B (en) Tyk2 inhibitors and uses thereof
HK40119624B (en) Tyk2 inhibitors and uses thereof
HK40065275A (zh) Tyk2抑制剂和其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40105557

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant